Unknown

Dataset Information

0

Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.


ABSTRACT: Contemporary paediatric clinical trials have improved 5-year event-free survival above 85% and 5-year overall survival above 90% in B-cell acute lymphoblastic leukaemia (ALL) in many study groups, whilst outcomes for T-cell ALL are still lagging behind by 5-10% in most studies. Several factors have contributed to this discrepant outcome. First, patients with T-cell ALL are generally older than those with B-cell ALL and, therefore, have poorer tolerance to chemotherapy, especially dexamethasone and asparaginase, and have increased risk of extramedullary relapse. Second, a higher proportion of patients with B-cell ALL have favourable genetic subtypes (eg, ETV6-RUNX1 and high hyperdiploidy), which confer a superior outcome compared with favourable subtypes of T-cell ALL. Third, T-cell ALL blasts are generally more resistant to conventional chemotherapeutic drugs than are B-cell ALL blasts. Finally, patients with B-cell ALL are more amendable to available targeted therapies, such as Philadelphia chromosome-positive and some Philadelphia chromosome-like ALL cases to ABL-class tyrosine kinase inhibitors, and CD19-positive and CD22-postive B-cell ALL cases to a variety of immunotherapies. Several novel treatments under investigation might narrow the gap in survival between T-cell ALL and B-cell ALL, although novel treatment options for T-cell ALL are limited.

SUBMITTER: Teachey DT 

PROVIDER: S-EPMC9233195 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.

Teachey David T DT   Pui Ching-Hon CH  

The Lancet. Oncology 20190301 3


Contemporary paediatric clinical trials have improved 5-year event-free survival above 85% and 5-year overall survival above 90% in B-cell acute lymphoblastic leukaemia (ALL) in many study groups, whilst outcomes for T-cell ALL are still lagging behind by 5-10% in most studies. Several factors have contributed to this discrepant outcome. First, patients with T-cell ALL are generally older than those with B-cell ALL and, therefore, have poorer tolerance to chemotherapy, especially dexamethasone a  ...[more]

Similar Datasets

| S-EPMC11464031 | biostudies-literature
2008-10-23 | GSE13280 | GEO
| S-EPMC3354740 | biostudies-literature
2008-11-13 | E-GEOD-13280 | biostudies-arrayexpress
| S-EPMC6889389 | biostudies-literature
| S-EPMC4207443 | biostudies-literature
| S-EPMC11763943 | biostudies-literature
| S-EPMC4754340 | biostudies-literature
| S-EPMC9539952 | biostudies-literature
| S-EPMC3816716 | biostudies-literature